The results of a clinical trial designed to assess the effectiveness and tolerability of fenquizone, a quinazolinone diuretic, in 20 patients with mild to moderately severe essential hypertension with associated obesity and impaired glucose tolerance are described. The test product was administered for 90 days in single daily doses of 10 mg. Recheck observations made at 30, 60, and 90 days of the trial revealed satisfactory and significant control of systolic and diastolic blood pressure with complete freedom from measurable effects on metabolism (fasting blood sugar, oral glucose tolerance test, uric acid, and blood total cholesterol, HDL-cholesterol and triglycerides) or on serum electrolytes (Na+ and K+). The authors conclude that fenquizone administered in single daily doses is an effective antihypertensive agent which can be safely employed also in patients with impaired glucose tolerance.
|Number of pages||8|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1984|
ASJC Scopus subject areas